From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
AHFS/Drugs.com monograph
MedlinePlus a692045
Legal status
Routes Intravenous
Pharmacokinetic data
Bioavailability n/a
Protein binding >99%
Metabolism Hepatic (CYP2C19-mediated)
Half-life 5 hours
Excretion Renal and fecal
CAS number 29767-20-2 YesY
ATC code L01CB02
PubChem CID 34698
DrugBank DB00444
ChemSpider 31930 N
UNII 957E6438QA N
KEGG D02698 YesY
Chemical data
Formula C32H32O13S 
Molecular mass 656.655 g/mol
 N (what is this?)  (verify)

Teniposide (Vumon, VM-26) is a chemotherapeutic medication[1] mainly used in the treatment of childhood acute lymphocytic leukemia (ALL). It is in a class of drugs known as podophyllotoxin derivatives and slows the growth of cancer cells in the body.

Mechanism of action[edit]

Teniposide causes dose-dependent single- and double-stranded breaks in DNA and DNA-protein cross-links. The mechanism of action appears to be related to the inhibition of type II topoisomerase activity since teniposide does not intercalate into DNA or bind strongly to DNA. The cytotoxic effects of teniposide are related to the relative number of double-stranded DNA breaks produced in cells, which are a reflection of the stabilization of a topoisomerase II-DNA intermediate.


The medication is injected though a vein and burns if it leaks under the skin. It is sometimes used in combination with other anticancer drugs.


Teniposide, when used with other chemotherapeutic agents for the treatment of ALL, results in severe myelosuppression. Other common side effects include gastrointestinal toxicity, hypersensitivity reactions, and alopecia.


  1. ^ Cragg, Gordon M.; Newman, David J. (2005). "Plants as a source of anti-cancer agents". Journal of Ethnopharmacology 100 (1–2): 72–9. doi:10.1016/j.jep.2005.05.011. PMID 16009521.